Christian B J, Kao C H, Wu S Q, Meisner L F, Reznikoff C A
Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison 53792.
Cancer Res. 1990 Aug 1;50(15):4779-86.
To determine if expression of mutant p21 ras could convert Simian Virus 40-immortalized human uroepithelial cell line (SV-HUC) to tumorigenicity, SV-HUC cells were transfected with pSV2-neo (a neomycin-resistant gene) or PREJ/ras (c-HA-ras-1 with the 12th codon mutation and neo). Seven independent G418-resistant clones (A----G) were isolated from each group (SV-HUC/ras and SV-HUC/neo). SV-HUC/ras clones were morphologically altered, while SV-HUC/neo clones retained a typical SV-HUC epithelial morphology. Electrophoretic analysis of immunoprecipitated ras proteins detected altered p21 ras protein in four of seven SV-HUC/ras clones at passage (P)2 and in five of seven clones at P12 posttransfection. The relative levels of ras p21 differed among the clones and appeared to increase with passage in culture. RNA and DNA dot blot analyses showed that clones with more abundant mutant p21 also had higher ras RNA levels and, in one case, increased ras gene copy number. No altered ras protein was detected in any SV-HUC/neo clones. ras- and neo-transfected clones were tested for tumorigenicity at P2 posttransfection and again at P12 by four s.c. inoculations each into athymic nude mice. None of 56 inoculations of SV-HUC/neo clones was tumorigenic. None of the SV-HUC/ras clones at P2 gave rise to tumors at all four injection sites. However, two ras-transfected clones, SV-HUC/ras-B and SV-HUC/ras-F, produced one tumor each. One clone, SV-HUC/ras-D which produced abundant mutant p21, was negative when inoculated at P2, but produced tumors in four of four sites when reinoculated after ten passages in vitro. All tumorigenic clones had detectable levels of mutant ras p21. However, the relative levels of altered p21 ras protein among the SV-HUC/ras clones did not directly predict their tumorigenic potential, as several nontumorigenic SV-HUC/ras clones had protein levels equal to or higher than the most tumorigenic clone (SV-HUC/ras-D at P12). Cell lines established from the tumor explants exhibited higher ras gene copy numbers, higher RNA levels, and more abundant p21 than was seen in the clones at the time of inoculation. Therefore, increases in ras protein abundance occurred during tumor formation in vivo, as well as during passage of cells in culture, and such cells apparently had a selective growth advantage. However, expression of abundant mutant ras protein was not in itself sufficient for neoplastic transformation of SV-HUC.(ABSTRACT TRUNCATED AT 400 WORDS)
为了确定突变型p21 ras的表达是否能使猿猴病毒40永生化的人尿道上皮细胞系(SV - HUC)具有致瘤性,将SV - HUC细胞用pSV2 - neo(一种新霉素抗性基因)或PREJ/ras(第12位密码子突变的c - HA - ras - 1和neo)进行转染。从每组(SV - HUC/ras和SV - HUC/neo)中分离出7个独立的G418抗性克隆(A - G)。SV - HUC/ras克隆在形态上发生了改变,而SV - HUC/neo克隆保留了典型的SV - HUC上皮形态。对免疫沉淀的ras蛋白进行电泳分析,发现在传代(P)2时,7个SV - HUC/ras克隆中有4个检测到p21 ras蛋白改变,转染后P12时,7个克隆中有5个检测到改变。各克隆中ras p21的相对水平不同,且似乎随着培养传代而增加。RNA和DNA斑点印迹分析表明,具有更丰富突变型p21的克隆也有更高的ras RNA水平,并且在一个案例中,ras基因拷贝数增加。在任何SV - HUC/neo克隆中均未检测到改变的ras蛋白。在转染后P2时对ras和neo转染的克隆进行致瘤性测试,并在P12时再次通过分别对无胸腺裸鼠进行4次皮下接种进行测试。56次接种的SV - HUC/neo克隆均无致瘤性。P2时的SV - HUC/ras克隆在所有4个注射部位均未产生肿瘤。然而,两个ras转染克隆,SV - HUC/ras - B和SV - HUC/ras - F,各产生了一个肿瘤。一个产生大量突变型p21的克隆SV - HUC/ras - D,在P2接种时为阴性,但在体外传代10次后重新接种时,在4个部位中有4个产生了肿瘤。所有致瘤性克隆均有可检测水平的突变型ras p21。然而,SV - HUC/ras克隆中改变的p21 ras蛋白的相对水平并不能直接预测其致瘤潜力,因为一些非致瘤性的SV - HUC/ras克隆的蛋白水平等于或高于最具致瘤性的克隆(P12时的SV - HUC/ras - D)。从肿瘤外植体建立的细胞系显示出比接种时克隆中更高的ras基因拷贝数、更高的RNA水平和更丰富的p21。因此,ras蛋白丰度的增加在体内肿瘤形成过程中以及细胞在培养传代过程中均会发生,并且此类细胞显然具有选择性生长优势。然而,大量突变型ras蛋白的表达本身并不足以使SV - HUC发生肿瘤转化。(摘要截短于400字)